定量超声生物标志物评估非酒精性脂肪性肝病
前瞻性纳入125名参与者,基于MRI-PDFF和MRE分组,评估超声衰减系数、归一化局部方差、SMI血管指数和剪切波速度诊断肝脂肪变和纤维化的效能。AC、NLV和SMI-VI诊断≥轻度脂肪肝的AUC分别为0.95、0.90和0.92,SWV诊断≥F1纤维化的AUC为0.93。肝纤维化可能影响AC定量肝脂肪含量的性能。
要点
- AC诊断≥轻度脂肪肝(MRI-PDFF≥5%)的AUC高达0.95,与MRI-PDFF相关性好(r=0.91)。
- SWV诊断≥F1肝纤维化的AUC为0.93,可用于无创评估纤维化。
- 肝纤维化(≥F1)会改变AC与MRI-PDFF的回归斜率,提示纤维化可能影响脂肪定量。
关键影像表现/征象
- AC、NLV和SMI-VI在三组间差异有统计学意义。
- NAFL组中MRI-PDFF与AC呈正相关(r=0.91),与NLV(r=-0.74)和SMI-VI(r=-0.8)呈负相关。
诊断标准与关键数值
- AC诊断≥轻度脂肪肝(MRI-PDFF≥5%)的AUC为0.95。
- NLV诊断≥轻度脂肪肝(MRI-PDFF≥5%)的AUC为0.90。
- SMI-VI诊断≥轻度脂肪肝(MRI-PDFF≥5%)的AUC为0.92。
- SWV诊断≥F1肝纤维化的AUC为0.93。
临床应用与阅片要点
- AC可作为无创定量肝脂肪含量的可靠指标,尤其适用于NAFL患者。
- SWV有助于筛查≥F1肝纤维化,辅助风险分层。
- 报告肝脂肪定量时需注意合并肝纤维化可能影响AC的准确性。
局限性
- 原文未明确报告研究局限。
- 单中心前瞻性研究,样本量有限,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess diagnostic performance of quantitative ultrasound (QUS) biomarkers in assessing hepatic steatosis.
METHODS: We prospectively recruited 125 participants (mean age 54 years) who underwent liver QUS, magnetic resonance imaging (MRI), and laboratory tests within 30 days in this IRB approved study. Based on MRI-proton density fat fraction (MRI-PDFF) and MRE, we divided 125 participants into normal liver, nonalcoholic fatty liver (NAFL) and liver fibrosis (≥F1) groups. We examined diagnostic performance of ultrasound attenuation coefficient (AC), normalized local variance (NLV), superb microvascular imaging-based vascularity index (SMI-VI), and shear wave velocity (SWV) for determining hepatic steatosis and fibrosis using area under receiver operating characteristic curve (AUC). We also analyzed correlations of QUS biomarkers to MRI using Spearman correlation coefficient.
RESULTS: We observed significant differences in AC, NLV, and SMI-VI among the three groups (22 participants with normal liver, 78 with NAFL, and 25 with liver fibrosis). AUC of AC, NLV, and SMI-VI for determining ≥ mild steatotic livers (MRI-PDFF ≥5%) was 0.95, 0.90, and 0.92, respectively. AUC of SWV for determining ≥ F1 liver fibrosis was 0.93. The correlation of MRI-PDFF was positive to AC (r = 0.91) and negative to NLV (r = -0.74), SMI-VI (r = -0.8) in NAFL group. There was a significant difference in regression slope of AC to MRI-PDFF in livers with and without ≥F1 (0.84 vs 0.91, P = .02).
CONCLUSIONS: QUS biomarkers have high sensitivity and specificity to determine and grade hepatic steatosis and detect liver fibrosis. The effect of liver fibrosis on the performance of QUS biomarkers in quantifying liver fat content warrants further investigation.
引用
- Gao, Zapata, Chen, et al. Quantitative Ultrasound Biomarkers to Assess Nonalcoholic Fatty Liver Disease. J Ultrasound Med. 2023. PMID: 36744595. doi:10.1002/jum.16185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。